SCHEMBL239190

SCHEMBL239190

COc1ccc(-c2cc3ncc(C=O)c(N)n3n2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 10/20 0.63
NPC1 O15118 9/20 0.63
SMN1; SMN2 Q16637 7/20 0.63
ALDH1A1 P00352 6/20 0.63
L3MBTL1 Q9Y468 2/20 0.63
STAT1 P42224 1/20 0.63
KDM4E B2RXH2 6/20 0.50
HPGD P15428 3/20 0.50
PKM P14618 1/20 0.50
CDK5 Q00535 1/20 0.50
CDK5R1 Q15078 1/20 0.50
AURKA O14965 1/20 0.48
MAPT P10636 5/20 0.46
NPSR1 Q6W5P4 2/20 0.45
RXFP1 Q9HBX9 2/20 0.45
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
ATM Q13315 1/20 0.45
GAA P10253 1/20 0.43
CYP2C9 P11712 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2755216 0.86 NPC1 (0.61) RAB9ANPC1SMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL239796 0.83 NPC1 (0.48) RAB9ANPC1SMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL240099 0.82 NPC1 (0.49) RAB9ANPC1SMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL3250171 0.81 NPC1 (0.64) RAB9ANPC1SMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL23657566 0.78 NPC1 (1.00) RAB9ANPC1SMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL237831 0.78 RAB9A (0.67) RAB9ANPC1SMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL238967 0.78 RAB9A (0.45) RAB9ANPC1SMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL236832 0.75 NPC1 (0.78) RAB9ANPC1SMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL235359 0.74 NPC1 (0.50) RAB9ANPC1SMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL239685 0.74 NPC1 (0.40) RAB9ANPC1SMN1; SMN2ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2406250-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2015-08-12 EP disclosed
EP-2406250-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2015-08-12 EP disclosed
US-8614221-B2 Inhibitors of Akt activity MERCK SHARP & DOHME CORP. (US) 2013-12-24 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY PIK3CD, PIK3CA, PIK3R5 RAB9A 778/4885NPC1 1127/4885SMN1; SMN2 3442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.